Orchid Pharma Ltd

Orchid Pharma Ltd has announced the closure of its trading window for the first quarter of the Financial Year 2026-27, ending June 30, 2026. This closure, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, will commence on July 01, 2026, and will remain open until 48 hours after the declaration of the unaudited limited reviewed financial results for the said quarter. All designated persons and those possessing Unpublished Price Sensitive Information are prohibited from trading in the company's securities during this period. The date for the Board of Directors' meeting to approve these financial results will be communicated separately.

Orchid Pharma Limited has received a copy of the order from the Hon'ble National Company Law Tribunal (NCLT), Chennai, approving the Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited and Orchid Pharma Limited. The order was pronounced on June 5, 2026, and made available on the NCLT website on June 11, 2026. The Appointed Date for the scheme is April 1, 2024. The merger will be effective upon completion of the steps outlined in the scheme, and Orchid Pharma will update the exchanges once it becomes effective.

Orchid Pharma Limited has received an order from the Goods and Service Department confirming the demand and recovery of an erroneously refunded amount of ₹1,67,07,937 along with applicable interest. The company believes the order is unjustified and unsustainable, and intends to file an appeal. The matter pertains to a period before the company's Corporate Insolvency Resolution Process (CIRP) and subsequent acquisition. Management is of the view that liabilities from the pre-acquisition period are addressed under the approved Resolution Plan, and therefore, the order is not expected to have a material impact on the company's financials or operations.

Orchid Pharma Limited announced that the National Company Law Tribunal (NCLT), Chennai, has sanctioned the scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited and Orchid Pharma Limited. This merger, effective from June 05, 2026, will see Dhanuka Laboratories transferred to and vested in Orchid Pharma on a going concern basis. The company will provide the official order copy once available from the NCLT.

Orchid Pharma Ltd's board meeting on May 25, 2026, approved the appointment of the Internal Auditor for the financial year 2026-27. The board also approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The results along with auditor reports are available on the company's website.

Orchid Pharma Ltd announced its audited standalone and consolidated financial results for the year ended March 31, 2026. The company reported total income of ₹866.57 Mn and net profit of ₹45.21 Mn for the year. The board also approved the appointment of an internal auditor for the financial year 2026-27.

Orchid Pharma Ltd's board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The results include a modified opinion for consolidated financial results and an unmodified opinion for standalone financial results. Revenue from operations stood at ₹811.33 Mn for the year ended March 31, 2026. The board also approved the appointment of the Internal Auditor for the Financial Year 2026-27.

Orchid Pharma Ltd's board approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The results include a modified opinion for consolidated financial results and an unmodified opinion for standalone financial results. The company's revenue from operations for the year ended March 31, 2026, stood at ₹811.33 million. The board also approved the appointment of the Internal Auditor for FY 2026-27.

Orchid Pharma Ltd has scheduled a Board of Directors meeting on May 25, 2026, to consider and approve the Audited Financial Results (Standalone & Consolidated) for Quarter-IV and the financial year 2025-26, which ended on March 31, 2026. The trading window for dealing in the company's securities has been closed from April 01, 2026, and will remain closed until 48 hours after the declaration of the said financial results.

Orchid Pharma Ltd has released the Monitoring Agency Report for Quarter IV of financial year 2025-26, ended March 31, 2026. The report, issued by CARE Ratings Limited, pertains to the utilization of proceeds raised through Qualified Institutions Placement (QIP). The monitoring agency declared no deviations from the stated objectives and confirmed that the utilization of funds is in line with the revised allocation schedule. The QIP involved an amount aggregating to ₹400 crores.